Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Background: Intragastric injection of botulinum toxin A (BT-A) has been shown to be effective for weight loss up to six months after administration, according to previous studies. Our objective was to determine, in patients on bariatric surgery waiting lists, the effect of BT-A on weight loss in the pre- and postoperative period and to analyse if there are different responses based on Body Mass Index (BMI). Methods: We performed a follow-up analysis of the IntraTox study, which included 46 patients on bariatric surgery waiting lists in a single-centre, randomised, double-blind, placebo-controlled clinical trial. The treatment group received intragastric BT-A, whereas the control group received physiological saline solution. The one-time procedure was performed at the time of diagnostic endoscopy 7–8 months before surgery. Weight loss was evaluated at admission and after 4 and 12 weeks from the bariatric surgery. Our analysis was stratified by BMI at randomisation. Results: weight loss percentage on the day of surgery, with respect to the initial visit, was −4.5 ± 3.9% for the control group vs. −7.6 ± 4.2%, for the treatment group (p = 0.013). Weight loss percentage tended to remain greater in the treatment group one month after the intervention (−12.7 ± 4.7% vs. −15.2 ± 4.6%, p = 0.07) and become similar three months after (−21.6 ± 4.7% vs. −21.6 ± 4.6%). After stratifying by BMI, only patients with BMI over 50 kg/m2 allocated to the treatment group obtained a greater weight loss at the end of the trial, the day of surgery, and one month after, compared with the placebo group (−4.9 ± 4.9%, −10.8 ± 5.3% and −17.1 ± 3.8% vs. −0.1 ± 2.6%, −4.3 ± 3.2% and −12.8 ± 4.1%, respectively (p < 0.05). Conclusions: intragastric injection of BT-A is effective to achieve significant weight loss, especially in extreme obesity. Its use before bariatric surgery enhances perioperative weight loss.

Details

Title
Endoscopic Intragastric Injection of Botulinum Toxin A in Obese Patients Accelerates Weight Loss after Bariatric Surgery: Follow-Up of a Randomised Controlled Trial (IntraTox Study)
Author
Sánchez-Torralvo, Francisco José 1   VIAFID ORCID Logo  ; Vázquez-Pedreño, Luis 2 ; Gonzalo-Marín, Montserrat 3 ; Tapia, María José 3   VIAFID ORCID Logo  ; Lima, Fuensanta 4 ; García-Fuentes, Eduardo 5   VIAFID ORCID Logo  ; García, Pilar 2 ; Moreno-Ruiz, Javier 6 ; Rodríguez-Cañete, Alberto 6 ; Valdés, Sergio 7 ; Olveira, Gabriel 7   VIAFID ORCID Logo 

 Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, 29010 Malaga, Spain; [email protected] (M.G.-M.); [email protected] (M.J.T.); [email protected] (F.L.); [email protected] (S.V.); [email protected] (G.O.); Departamento de Medicina y Dermatología, Facultad de Medicina, University of Malaga, 29010 Malaga, Spain; Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Malaga, Spain; [email protected] 
 Unidad de Endoscopias, Unidad de Gestión Clínica de Aparato Digestivo, Hospital Regional Universitario de Málaga, 29010 Malaga, Spain; [email protected] (L.V.-P.); [email protected] (P.G.) 
 Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, 29010 Malaga, Spain; [email protected] (M.G.-M.); [email protected] (M.J.T.); [email protected] (F.L.); [email protected] (S.V.); [email protected] (G.O.); Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Malaga, Spain; [email protected]; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain 
 Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, 29010 Malaga, Spain; [email protected] (M.G.-M.); [email protected] (M.J.T.); [email protected] (F.L.); [email protected] (S.V.); [email protected] (G.O.); Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Malaga, Spain; [email protected] 
 Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Malaga, Spain; [email protected]; Unidad de Gestión Clínica de Aparato Digestivo, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28029 Madrid, Spain 
 Unidad de Gestión Clínica de Cirugía General y Digestiva, Hospital Regional Universitario de Málaga, 29010 Malaga, Spain; [email protected] (J.M.-R.); [email protected] (A.R.-C.) 
 Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, 29010 Malaga, Spain; [email protected] (M.G.-M.); [email protected] (M.J.T.); [email protected] (F.L.); [email protected] (S.V.); [email protected] (G.O.); Departamento de Medicina y Dermatología, Facultad de Medicina, University of Malaga, 29010 Malaga, Spain; Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Malaga, Spain; [email protected]; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain 
First page
2126
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
20770383
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2652976098
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.